Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lingfeng Yang

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Alzheimer'S Research & Therapy|May 14, 2016
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trialsRik Vandenberghe, Juha O Rinne, Mercè Boada, et al.
Frontiers in Endocrinology|April 24, 2023
Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trialZhijie Dai, Ronghua Zhu, Zhifeng Sheng, et al.
Nature Communications|May 16, 2013
Draft genome sequence of the Tibetan antelopeRi-Li Ge, Qingle Cai, Yong-Yi Shen, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Journal for Immunotherapy of Cancer|March 16, 2019
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 studyAsim Amin, Elizabeth R Plimack, Marc S Ernstoff, et al.
Alzheimer'S Research & Therapy|May 14, 2016
Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trialsRik Vandenberghe, Juha O Rinne, Mercè Boada, et al.
Frontiers in Endocrinology|April 24, 2023
Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trialZhijie Dai, Ronghua Zhu, Zhifeng Sheng, et al.
Nature Communications|May 16, 2013
Draft genome sequence of the Tibetan antelopeRi-Li Ge, Qingle Cai, Yong-Yi Shen, et al.
Pageof 7